Home > Journals > Minerva Oftalmologica > Past Issues > Minerva Oftalmologica 2002 June;44(2) > Minerva Oftalmologica 2002 June;44(2):103-6

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

MINERVA OFTALMOLOGICA

A Journal on Ophthalmology


eTOC

 

  GLAUCOMA


Minerva Oftalmologica 2002 June;44(2):103-6

language: English

Maximal medical therapy for glaucoma: know when to say when

Singh K., Fechtner R. D.


Full text temporarily not available online. Contact us  


A decade ago, maximal medical therapy generally consisted of three classes of glaucoma medications. With the introduction of prostaglandin derivatives, selective alpha-adrenergic agonists and topical carbonic anhydrase inhibitors we have many more choices with regard to adjunctive medical therapy. The availability of so many classes of IOP lowering medications and several agents in each class have made it impractical to try every agent prior to giving up on medical therapy and moving on to surgical alternatives. Since the magnitude of expected IOP lowering is dependant, in part, on the level of IOP prior to treatment, one generally sees diminishing returns when adding medications on top of others that have already lowered IOP. Some of the other problems associated with the use of multiple glaucoma medications include the difficulty in detecting tachyphylaxis, increased fluctuation in IOP, preservative related ocular toxicity, other ocular and systemic side effects as well as cost. Most glaucoma patients should be treated with the one or two glaucoma medications that are most likely to adequately lower IOP with minimal side effects. While the addition of a third agent is sometimes warranted, it rarely makes sense to treat a patient with four or more glaucoma medications simultaneously. Non medical therapeutic options should be considered in such patients.

top of page

Publication History

Cite this article as

Corresponding author e-mail